.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Covington
Fuji
US Army
Federal Trade Commission
Accenture
Dow
Julphar
McKesson
Moodys

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Try a Free Trial

« Back to Dashboard

Details for Patent: ➤ Try a Free Trial

Title:Therapeutic compositions containing macitentan
Abstract: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. ##STR00001##
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH)
Filing Date:Aug 12, 2009
Application Number:13/058,639
Claims:1. A product containing macitentan or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof selected from 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide and its pharmaceutically acceptable salts, and {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid and its pharmaceutically acceptable salts.

2. A product according to claim 1, wherein the compound having prostacyclin receptor (IP) agonist properties or a pharmaceutically acceptable salt thereof is {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid and its pharmaceutically acceptable salts.

3. A product according to claim 1, wherein the compound having prostacyclin receptor (IP) agonist properties or a pharmaceutically acceptable salt thereof is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide or a pharmaceutically acceptable salt thereof.

4. A method for the treatment of a disease wherein endothelin is involved, is selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction, angina pectoris and pulmonary fibrosis comprising administering an effective amount of a product of claim 1.

5. The method according to claim 4, wherein the compound having prostacyclin receptor (IP) agonist properties or a pharmaceutically acceptable salt thereof is {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid and its pharmaceutically acceptable salts.

6. The method according to claim 4, wherein the compound having prostacyclin receptor (IP) agonist properties or a pharmaceutically acceptable salt thereof is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide or a pharmaceutically acceptable salt thereof.

7. The method according to claim 4, wherein the disease wherein endothelin is involved is pulmonary arterial hypertension.

8. The method according to claim 4, wherein the disease wherein endothelin is involved is pulmonary hypertension.

9. A pharmaceutical composition containing, as active principles, macitentan, or a pharmaceutically acceptable salt thereof, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof selected from 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide and its pharmaceutically acceptable salts, and {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid and its pharmaceutically acceptable salts, as well as at least one pharmaceutically acceptable excipient.

10. A pharmaceutical composition according to claim 9, wherein the compound having prostacyclin receptor (IP) agonist properties or pharmaceutically acceptable salt thereof is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Argus Health
Novartis
Boehringer Ingelheim
Julphar
Merck
Deloitte
Baxter
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot